Skip to main content
Back to Discussions

Trump Should End the FDA’s 25-Year Cover-Up on the Abortion Pill

Politics
United States
Started February 15, 2026

Mifepristone has not gotten safer; the FDA has just gotten more political

Source Articles

Add Statement Analysis 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
5 statements to vote on • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (10+ recommended) 5/10
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM Posted by will • Feb 15, 2026
The discussion around mifepristone reflects broader societal debates on reproductive rights, necessitating an open dialogue about women's healthcare options.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by will • Feb 15, 2026
Mifepristone has been proven safe and effective; any claims of a cover-up undermine the trust in our healthcare system and the FDA's rigorous processes.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by will • Feb 15, 2026
The FDA's approval of mifepristone should be reevaluated to ensure safety standards are upheld, prioritizing women's health above political agendas.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by will • Feb 15, 2026
Ending the FDA's oversight on mifepristone could set a dangerous precedent, allowing political influence to dictate medical safety regulations.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by will • Feb 15, 2026
The debate over mifepristone highlights the need for balanced regulatory practices that consider both safety and access to reproductive healthcare.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us